Australian biomarker model identifies Crohn’s patients for early biologic treatment

Australian researchers have developed a biomarker-derived model for predicting which patients with Crohn’s disease will benefit from early biologic therapy. The Crohn’s Immunomodulator CRP-Albumin (CICA) Index uses the readily available measures of an elevated CRP and low albumin to predict the likelihood of immunomodulator failure. A retrospective study of 410 adults with luminal Crohns’ disease ...

Already a member?

Login to keep reading.

© 2021 the limbic